(HealthDay News) — Population-based fecal immunochemical testing (FIT) screening in adults aged 50–69 years can reduce colorectal cancer (CRC) mortality, according to a study published online May 20 in Cancer.
Han-Mo Chiu, PhD, from National Taiwan University, and colleagues conducted a prospective study of the follow-up of about five million Taiwanese from 2004–2009. CRC mortality was compared for a screened group and an unscreened group in a population-based CRC screening service targeting 50–69-year-olds. Overall, 21.4% of the 5,417,699 subjects aged 50–69 years in the population participated in the biennial screening program by 2009.
The researchers found that, with a maximum follow-up of six years, the actual effectiveness of FIT in reducing CRC mortality was 62% (relative rate for screened vs. unscreened group, 0.38). After adjustment for self-selection bias, the 21.4% coverage of the population receiving FIT correlated with a significant 10% reduction in CRC mortality (relative rate, 0.9).
“Although such findings are informative for health decision makers, continued follow-up of this large cohort will be required to estimate the long-term impact of FIT screening if the covered population is expanded,” the authors write.